Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

Plectranthus ornatus withers in Luxembourg: Ralf Schräder v CPVO (IPKat) (ipwars.com)

District Court Delaware declines to stay Integrilin case, putting Teva at risk of forfeiting 180-day exclusivity: Millennium Pharms. and Schering Corp. v. Teva (Orange Book Blog) (FDA Law Blog)

Global agreement drafting expertise for pharma and biotech (IP Think Tank)

GSK Senior Vice President to start IP consulting firm (Patent Docs)

Committee examines undue influence, coordination in WHO pandemic flu response (IP Watch)

UNITAID patent pool budget approved; implementation to begin (IP Watch)

Fight against counterfeit of medicinal products – International Medicrime Conference (IP tango)

Canada: Therapeutic Products Directorate Statistical Report 2008 PMNOC Regulations released (Pharmacapsules)

Canada: Guidance document regarding generic veterinary drugs (Pharmacapsules)

Canada: Federal Court affirms Minister’s NDS refusal (drug unknown): Hospira v Attorney General (Pharmacapsules)

Ecuador’s compulsory licensing regime for medicines (IP tango)

EU: SPCs, actives and medical devices (The SPC Blog)

EU: Plectranthus ornatus withers in Luxembourg: Ralf Schräder v CPVO (IPKat) (ipwars.com)

India: OPPI responds to IPA’s claims of frivolous patenting by its member companies (Spicy IP)

India: To be or not to be 3(d) (Spicy IP)

India: Leveraging oppositions for a ‘never green’ patent system (Spicy IP)

India: National Biological Authority to organise national consultation on proposed ‘benefit sharing protocols’ and ‘traditional knowledge rules’ (Spicy IP)

US: Initial comment on Ariad: Written description and the baseline of patent protection for after-arising technology (Patently-O)

US: ‘Colbert Report’ enters gene patenting fray (Patent Docs)

US: The fantastical economics of the gene patenting debate (Patent Docs)

Actonel (Risedronate) – US: District Court N D West Virginia: Patent infringement complaint following Para IV challenge: Warner Chilcott et al v Mylan (Patent Docs)

Alli (Leucine) / NicodermCQ (Subsaturated nicotine transdermal therapeutic system) – US: District Court W D Tennessee: False marking complaint: Baker v GlaxoSmithkline Healthcare (Patent Docs)

Altace (Ramipril) – Canada: Federal Court: Motion to strike in s 8 case: Sanofi and Schering v Novopharm (Pharmacapsules)

Aplenzin (Buproprion) – US: District Court Minnesota: Patent infringement complaint following Para IV challenge: Biovail Laboratories International SRL v. Paddock Laboratories, Inc. (Patent Docs)

Baytril / Cipro / Ciprodex / Fludara / Legend / Proleukin – US: District Court W D Tennessee: False marking complaint: Baker v Bayer Aktiengescellschaft Corp. et al. (Patent Docs)

Bystolic (Nebivolol) – Austrian Supreme Court on limitation of patent claims: Case no 17 Ob 24/09t (EPLAW)

Denegard / Milbemite / Ocupress – US: District Court W D Tennessee: False marking complaint: Baker v Novartis Pharmaceuticals et al (Patent Docs)

Felbatol (Felbamate) – US: CAFC affirms District Court decision enforcing settlement agreement regarding the transfer of patent ownership: MedPointe Healthcare, Inc v Kozachuk (not precedential) (Patent Docs)

Husar (Jodosulfuron) – EU: ECJ to hear Rechtsanwaltssozietät Lovells v Bayer CropScience AG concerning SPCs for plant protection products on Thursday 22 April (The SPC Blog)

Integrilin (Eptifibatide) – US: District Court Delaware declines to stay Integrilin case, putting Teva at risk of forfeiting 180-day exclusivity: Millennium Pharms. and Schering Corp. v. Teva (Orange Book Blog) (FDA Law Blog)

Levistra (Vardenafil) – US: District Court Delaware: Patent infringement complaint following ANDA filing: Bayer Schering Pharma AG et al v Teva Pharmaceuticals USA, Inc et al (Patent Docs)

Nexavar (Sorafenib) – India: Bayer sues Cipla for infringement of Nexavar patent before Delhi High Court (Spicy IP)

Norfloxacin – Canada: Federal Court: Judgment in s 8 proceeding: Apotex v Merck (Pharmacapsules)

Prandin (Repaglinide) – US: CAFC vacates injunction that directed Novo Nordisk to revise patent use code for Pradin: Novo Nordisk v Caraco Pharm. Labs. et al (Orange Book Blog) (FDA Law Blog)

Seroquel (Quetiapine) – US: District Court New Jersey: Patent infringement complaint following Para IV challenge: Astrazeneca et al v Anchen Pharmaceuticals et al (Patent Docs)

Simcor (Niacin, Simvastatin) – US: District Court Delaware: Patent infringement complaint following Para IV challenge: Abbott Laboratories et al. v. Teva Pharmaceutical Industries Ltd. et al. (Patent Docs)

Xibrom (Bromfenac) – US: District Court W D Tennessee: False marking complaint: Baker v Bausch & Lomb, Inc (Patent Docs)

Zyprexa (Olanzapine) – Canada: Court denies Novopharm’s motion for Mareva injunction: Lilly v Novopharm (Pharmacapsules)